Tumors with higher PD-L1 expression tend to have better response rates to anti-PD-1 treatments in many types of cancer, and current evidence in HNSCC suggests that combined positive score (the sum total of PD-L1–positive tumor cells, lymphocytes, and macrophages divided by the total number of tumor cells) acts as an effective evaluation to screen patients for immunotherapy (10). Here, CD274 is linked to head and neck squamous cell carcinoma.